PGGM Investments Reduces Holdings in Cencora, Inc. (NYSE:COR)

PGGM Investments lessened its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 23.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,993 shares of the company's stock after selling 19,167 shares during the quarter. PGGM Investments' holdings in Cencora were worth $14,153,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of COR. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co purchased a new stake in Cencora in the fourth quarter valued at $33,000. Householder Group Estate & Retirement Specialist LLC grew its position in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the period. Finally, WASHINGTON TRUST Co raised its stake in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

NYSE:COR traded up $2.08 during trading hours on Friday, reaching $258.09. 925,102 shares of the company were exchanged, compared to its average volume of 1,356,105. The stock's 50-day moving average is $247.59 and its 200-day moving average is $239.09. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $263.70. The firm has a market cap of $50.05 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent research reports. Mizuho started coverage on Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price on the stock. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $280.20.

Insider Buying and Selling

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. The trade was a 9.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.